(194 days)
When the TxCell Scanning Laser Delivery System is connected to the IQ 532 (532 nm), the IQ 577 (577 nm) or the IQ 810 (810 nm) Laser Console, from the IRIDEX Family of IQ Laser Systems and used to deliver laser energy in CW-Pulse, MicroPulse or LongPulse mode, it is intended to be used by a trained ophthalmologist for the treatment of ocular pathology of both the anterior and posterior segments of the eye.
532 nm: Indicated for retinal photocoagulation, laser trabeculoplasty, iridotomy, iridoplasty including: Retinal photocoagulation (RPC) for the treatment of: Diabetic retinopathy, including: Nonproliferative retinopathy, Macular edema, Proliferative retinopathy; Retinal tears and detachments; Lattice degeneration; Age-related macular degeneration (AMD) with choroidal neovascularization (CNV); Sub-retinal (choroidal) neovascularization; Central and branch retinal vein occlusion; Laser trabeculoplasty for the treatment of: Primary open angle glaucoma; Laser iridotomy, iridoplasty for the treatment of: Angle closure glaucoma.
577 nm: Indicated for use in photocoagulation of both anterior and posterior segments including: Retinal photocoagulation, panretinal photocoagulation of vascular and structure abnormalities of the retina and choroid including: Proliferative and nonproliferative diabetic retinopathy; Choroidal neovascularization; Branch retinal vein occlusion; Age-related macular degeneration (AMD) with choroidal neovascularization (CNV); Retinal tears and detachments; Laser trabeculoplasty for the treatment of: Primary open angle glaucoma; Laser iridotomy, iridoplasty for the treatment of: Angle closure glaucoma.
810 nm: Indicated for retinal photocoagulation, laser trabeculoplasty, iridotomy including: Retinal photocoagulation for the treatment of: Diabetic retinopathy, including: Nonproliferative retinopathy, Macular edema, Proliferative retinopathy; Retinal tears, detachments and hole; Lattice degeneration; Age-related macular degeneration (AMD) with choroidal neovascularization (CNV); Sub-retinal (choroidal) neovascularization; Central and branch retinal vein occlusion; Laser trabeculoplasty for the treatment of: Primary open angle glaucoma; Laser iridotomy, iridoplasty for the treatment of: Angle closure glaucoma.
The TxCell™ Scanning Laser Delivery System is a slit lamp adapter laser delivery system which is installed by the customer on existing slit lamps in their office or clinic and is used by ophthalmologists to deliver laser energy to various ocular targets. The TxCell™ delivery system delivers laser applications in both single spot mode and multi-spot mode. The TxCell™ Scanning Laser Delivery System adds the use of multi-spot pattern scanning technology when coupling with commercially available IRIDEX laser systems. This offers existing IRIDEX laser systems the ability to deliver, in addition to standard single spot applications, a full spectrum of multi-spot pattern scanning options through a variety of customer owned slit lamps. The TxCell™ Scanning Laser Delivery System consists of the following system components: TxCell™ Scanning Slit Lamp Adapter (SSLA) that may be coupled to Zeiss-style or Haag Streit-style slit lamps or the IRIDEX Laser Workstations. TxCell™ Control Box with power supply, scanner controller, drive electronics and electrical connections. The Control Box is paired with an SSLA. Cables to connect the SSLA to the Control Box and the Control Box to the laser console. The TxCell Scanning Laser Delivery System requires connection to a TxCell compatible Laser Console from the IRIDEX Family of IQ Laser Systems (IQ 532, IQ 577, IQ 810). The touchscreen on the TxCell compatible IQ Family Laser Console accesses a Pattern Selection Screen and the knobs on the Laser Console set the pattern parameters. All other user interface screens and menus are unchanged and operate the same as on the standard IQ Family Laser Console.
The provided 510(k) summary for the TxCell™ Scanning Laser Delivery System focuses on bench testing to demonstrate the device's performance and substantial equivalence to predicate devices, rather than clinical studies involving human patients or complex AI algorithms. Therefore, many of the requested categories related to human subject studies (e.g., sample size for test set, experts for ground truth, MRMC study, training set details) are not applicable in this context.
Here's a breakdown of the available information:
1. Table of Acceptance Criteria and Reported Device Performance:
| Acceptance Criteria (Implicit from Testing) | Reported Device Performance |
|---|---|
| Control pulse-to-pulse power variations (single and multi-spot) | Better than 0.5% |
| Control duration variability (single and multi-spot) | Less than 0.25% |
| Consistency of output energy (single and multi-spot, CW & MicroPulse) | Consistently delivered |
| Spatial positioning independence of pulse-to-pulse variations | Pulse to pulse variations are controlled by the laser console and are independent of spatial positioning due to changes in spot location by the scanner. |
2. Sample size used for the test set and the data provenance:
- Sample Size: Not explicitly stated as a number of "samples" in the traditional sense of a clinical study. The test involved measurements of laser output power and duration.
- Data Provenance: Bench testing, performed by IRIDEX Corporation.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
- Not Applicable. The "ground truth" for this engineering bench test is the precise measurements taken by calibrated instruments. No human experts were involved in establishing a "ground truth" in the diagnostic sense.
4. Adjudication method for the test set:
- Not Applicable. No human adjudication was involved. The evaluation was based on direct instrumental measurements.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
- No. This device is a laser delivery system, not an AI-powered diagnostic or assistive technology for human readers. Therefore, an MRMC study comparing human readers with and without AI assistance is not relevant.
6. If a standalone (i.e. algorithm only, without human-in-the-loop performance) was done:
- Yes, in essence. The testing performed was standalone for the device's physical performance characteristics (laser output). There is no "algorithm" in the AI sense for this device. The device's performance was evaluated independently without human intervention during the measurement process.
7. The type of ground truth used:
- Instrumental measurements/engineering specifications. The ground truth was established by direct measurement of physical parameters (power, duration).
8. The sample size for the training set:
- Not Applicable. This device is hardware for laser delivery, not an AI or machine learning system that requires a "training set."
9. How the ground truth for the training set was established:
- Not Applicable. No training set was used.
{0}------------------------------------------------
510(k) Summary Section 5: TxCell™ Scanning Laser Delivery System
NOV 2 8 2012
Trade Name A.
TxCellTM Scanning Laser Delivery System
B. Common Name
Scanning Photocoagulator Slit Lamp Adapter Delivery System
C. Device Classification
Laser Instrument, Surgical, Powered (21CFR 878.4810)
D. Product Code:
GEX
E. Establishment Registration Number
2939653
Manufacturer's Identification F.
IRIDEX Corporation 1212 Terra Bella Ave. Mountain View, CA 94043-1824 (650) -962-8848 Ext. 8872 (650) 940-4710 (FAX)
Official Correspondent
Paul Hardiman Vice President Regulatory Affairs/Quality Assurance phardiman@iridex.com
G. Performance Standards
Bench testing was performed to compare the laser output variations of single spot and multispot scanned applications using the TxCell Scanning Laser Delivery System and a compatible Laser Console. Variations in continuous wave and MicroPulse laser applications were also assessed for both single spot and multi-spot delivery. Results showed that the laser system controls pulse to pulse power variations for both single spot and multi-spot scanning modes to better than 0.5%; and that the duration variability for both single spot and multi-spot scanning modes was less than 0.25%. The test confirmed that the output energy from the TxCell Scanning Laser Delivery System was consistently delivered in both single spot and multi-spot modes while delivering either continuous wave or MicroPulse laser applications. Pulse to pulse variations are controlled by the laser console and are independent of spatial positioning due to changes in spot location by the scanner.
IRIDEX Corporation 510(k) Submission for: TxCell Scanning Laser Delivery System
Section 5: 510(k) Summary - Page 5-1
{1}------------------------------------------------
H. Predicate Devices:
Family of IRIDEX IQ Laser Systems (IQ 532, IQ 577, IQ 630-670, IQ 810) (K071687) Quantel SUPRA SCANTM Delivery System (K100678) Topcon PASCAL Streamline 577 (K111108)
I. Product Description:
'
The TxCell™ Scanning Laser Delivery System is a slit lamp adapter laser delivery system which is installed by the customer on existing slit lamps in their office or clinic and is used by ophthalmologists to deliver laser energy to various ocular targets. The TxCell™ delivery system delivers laser applications in both single spot mode and multi-spot mode.
The TxCell™ Scanning Laser Delivery System adds the use of multi-spot pattern scanning technology when coupling with commercially available IRIDEX laser systems. This offers existing IRIDEX laser systems the ability to deliver, in addition to standard single spot applications, a full spectrum of multi-spot pattern scanning options through a variety of customer owned slit lamps.
The TxCell™ Scanning Laser Delivery System consists of the following system components:
- TxCell™ Scanning Slit Lamp Adapter (SSLA) that may be coupled to Zeiss-style 1. or Haag Streit-style slit lamps or the IRIDEX Laser Workstations.
- TxCell™ Control Box with power supply, scanner controller, drive electronics and 2. electrical connections. The Control Box is paired with an SSLA.
- . 3. Cables to connect the SSLA to the Control Box and the Control Box to the laser console.
The TxCell Scanning Laser Delivery System requires connection to a TxCell compatible Laser Console from the IRIDEX Family of IQ Laser Systems (IQ 532, IQ 577, IQ 810). The touchscreen on the TxCell compatible IQ Family Laser Console accesses a Pattern Selection Screen and the knobs on the Laser Console set the pattern parameters. All other user interface screens and menus are unchanged and operate the same as on the standard IQ Family Laser Console.
IRIDEX Corporation 510(k) Submission for: TxCell Scanning Laser Delivery System
Section 5: 510(k) Summary - Page 5-2
{2}------------------------------------------------
Summary of Technological Characteristics દ્વાન
The technological characteristics of the TxCell Scanning Laser Delivery System when coupling with commercially available IRIDEX laser systems (IQ 532, IQ 577 & IQ 810) are substantially equivalent to those of the predicate devices.
| Manufacturer | IRIDEX Corporation | IRIDEX Corporation | QUANTEL MEDICAL | TOPCONCorporation |
|---|---|---|---|---|
| DeviceDescription | TxCellTMScanning Laser DeliverySystem w/ IQ Family Laser(IQ 532, IQ 577, IQ 810) | EasyFitTMSlit Lamp Adapterw/ IQ Family Laser(IQ 532, IQ 577, IQ 810) | SUPRA SCANTMDelivery Systemw/ SUPRA 532 | PASCAL® Streamline577 |
| 510 (k) Number | K121475 | K071687 | K100678 | K111108 |
| Treatment LaserWavelengths | 532 nm,577 nm, 810 nm | 532 nm,577 nm,810 nm | 532 nm | 577 nm |
| Treatment LaserSources | Frequency doubled solid-state(532 nm, 577 nm) and directdiode (810 nm) | Frequency doubled solid-state (532 nm, 577 nm) anddirect diode (810 nm) | Frequency doubled solid-state | Frequency doubledsolid-state |
| Treatment LaserPower | Up to 2 W | Up to 5 W | Up to 2 W | Up to 2 W |
| Duty Cycle | Variable | Variable | Not reported | 100% |
| Repetition Mode | Available with single spotmode only | Available with single spotmode only | Not reported | Available with singlespot mode only |
| Aiming Beam λ(power output) | 635 nm; Direct diode(adjustable to < 1mW) | 635 nm; Direct diode(adjustable to < 1mW) | 635 nm | 635 nm; Direct diode(adjustable to < 1mW) |
| Type of DeliverySystem | Slit lamp adapter with opticalfiber connected to a separatelaser source | Slit lamp adapter withoptical fiber connected to aseparate laser source | Slit lamp adapter withoptical fiber connected toa separate laser source | Slit lamp adapter withoptical fiber withintegrated laser source |
| Laser DeliveryModes | Single spot & Multi-spotpatterns | Single spot | Single spot & Multi-spotpatterns | Single spot & Multi-spot patterns |
| Range of spot sizes forsingle spot mode | 50 - 500 μm | 50 - 500 μm | 50 - 500 μm | 60-400 μm |
| Range of spot sizes formulti-spot mode | 100 - 500 μm | na | 100-500 μm | 100 - 400 μm |
K. Rationale for Substantial Equivalence
The TxCell Scanning Laser Delivery System shares the same or similar indications for use, design features, functional features with, and therefore is substantially equivalent to, the predicate devices.
The TxCell™ Scanning Laser Delivery System is found to be substantially equivalent to the predicate devices.
IRIDEX Corporation 510(k) Submission for: TxCell Scanning Laser Delivery System
{3}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three stripes forming its wing and body. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the eagle.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
Iridex, Corporation % Mr. Paul H. Hardiman Vice President, Regulatory Affairs and Quality Assurance 1212 Terra Bella Avenue Mountain View. California 94043
November 28, 2012
Re: K121475
Trade/Device Name: TxCell™ Scanning Laser Delivery System Regulation Number: 21 CFR 878.4810 Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology Regulatory Class: Class II Product Code: GEX Dated: November 07, 2012
Received: November 19, 2012
Dear Mr. Hardiman:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drue, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA). it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical
{4}------------------------------------------------
Page 2 – Mr. Paul H. Hardiman
device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Peter D. Rumm -S
Mark N. Melkerson Acting Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{5}------------------------------------------------
240(K) INDICATIONS FOR USE STATEMENT
K121475 510(k) Number (if known):
??
Device Name: TxCell™ Scanning Laser Delivery System
Indications for Use:
When the TxCell Scanning Laser Delivery System is connected to the IQ 532 (532 nm), the IQ 577 (577 nm) or the IQ 810 (810 nm) Laser Console, from the IRIDEX Family of IQ Laser Systems and used to deliver laser energy in CW-Pulse, MicroPulse or LongPulse mode, it is intended to be used by a trained ophthalmologist for the treatment of ocular pathology of both the anterior and posterior segments of the eye.
532 nm
Indicated for retinal photocoagulation, laser trabeculoplasty, iridotomy, iridoplasty including:
Retinal photocoagulation (RPC) for the treatment of:
Diabetic retinopathy, including:
Nonproliferative retinopathy
- Macular edema
- Proliferative retinopathy
Retinal tears and detachments
Lattice degeneration
Aqe-related macular degeneration (AMD) with choroidal neovascularization (CNV) Sub-retinal (choroidal) neovascularization
Central and branch retinal vein occlusion
- Laser trabeculoplasty for the treatment of: Primary open angle glaucoma
Laser iridotomy, iridoplasty for the treatment of: Angle closure glaucoma
Over-The-Counter Use Prescription Use AND/OR X (21 CFR 801 Subpart C) (Part 21 CFR 801 Subpart D) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)
Neil R Ogden
2012.11.28 14:41:48 -05'00'
(Division Sign-Off) 205 MAN Division of Surgical Devices 510(k) Number _K121475
IRIDEX Corporation 510(k) Submission for: TxCell Scanning Laser Delivery System
Section 4: Indications for Use - Page 4-1
{6}------------------------------------------------
210(K) INDICATIONS FOR USE STATEMENT
510(k) Number (if known):
Device Name: IxCell™ Scanning Laser Delivery System
577 nm
Indicated for use in photocoagulation of both anterior and posterior segments including:
Retinal photocoagulation, panretinal photocoagulation of vascular and structure abnormalities of the retina and choroid including:
Proliferative and nonproliferative diabetic retinopathy
Choroidal neovascularization
Branch retinal vein occlusion
Age-related macular degeneration (AMD) with choroidal neovascularization (CNV) Retinal tears and detachments
Laser trabeculoplasty for the treatment of: Primary open angle glaucoma
Laser iridotomy, iridoplasty for the treatment of: Angle closure glaucoma
| Prescription Use(Part 21 CFR 801 Subpart D) | X | AND/OR | Over-The-Counter Use(21 CFR 801 Subpart C) | |
|---|---|---|---|---|
| ------------------------------------------------- | --- | -------- | ------------------------------------------------ | -- |
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Neil R Ogden
2012.11.28 14:43:05 -05'00'
(Division Sign-Off) for mxm
| Division of Surgical Devices | |
|---|---|
| 510(k) Number | K121475 |
IRIDEX Corporation 510(k) Submission for: TxCell Scanning Laser Delivery System
Section 4: Indications for Use - Page 4-2
{7}------------------------------------------------
૨૫૦(K) INDICATIONS FOR USE STATEMENT
・ 510(k) Number (if known): K121475
Device Name: TxCell™ Scanning Laser Delivery System
810 nm
Indicated for retinal photocoagulation, laser trabeculoplasty, iridotomy including:
Retinal photocoagulation for the treatment of: Diabetic retinopathy, including: Nonproliferative retinopathy Macular edema Proliferative retinopathy Retinal tears, detachments and hole Lattice degeneration Age-related macular degeneration (AMD) with choroidal neovascularization (CNV) Sub-retinal (choroidal) neovascularization Central and branch retinal vein occlusion
Laser trabeculoplasty for the treatment of: Primary open angle glaucoma
Laser iridotomy, iridoplasty for the treatment of: Angle closure glaucoma
| Prescription Use | X | AND/OR | Over-The-Counter Use | |
|---|---|---|---|---|
| (Part 21 CFR 801 Subpart D) | (21 CFR 801 Subpart C) | |||
| (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) | ||||
| Concurrence of CDRH, Office of Device Evaluation (ODE) |
Neil R Ogden
2012.11.28 14:43:33 -05'00'
| (Division Sign-Off) | n MXm |
|---|---|
| Division of Surgical Devices | |
| 510(k) NumberK121475 |
IRIDEX Corporation 510(k) Submission for: TxCell Scanning Laser Delivery System
Section 4: Indications for Use - Page 4-3
§ 878.4810 Laser surgical instrument for use in general and plastic surgery and in dermatology.
(a)
Identification. (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
(b)
Classification. (1) Class II.(2) Class I for special laser gas mixtures used as a lasing medium for this class of lasers. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.